Category: Edwards Lifesciences
Edwards Lifesciences shares slide more than 5% after the medical device company forecasts sales for its flagship Sapien replacement heart valve for next year that miss analysts' expectations.
A conservative forecast for 2014 sent shares of Edwards Lifesciences (NYSE:EW) down more than 5% yesterday and kept them flat today, as the medical device company said it expects more competition next year for its flagship Sapien replacement heart valve.
California medical device giant Edwards Lifesciences names Scott Ullem to replace retiring finance chief Thomas Abate.
Medtech titan Edwards Lifesciences (NYSE:EW) today named Scott Ullem its new chief financial officer, replacing retiring CFO Thomas Abate. Ullem will take on the role at the start of 2014.
The Sapien replacement heart valve fares as well in the real world as it did during clinical trials, according to an analysis in the Journal of the American Medical Assn.
Medtronic says a German court lifted the ban on sales there of its CoreValve replacement heart valve, meaning it can resume sales of the transcatheter aortic valve implant as soon as it posts a roughly $6.7 million bond.
Edwards Lifesciences expands its heart valve manufacturing facility in Singapore, doubling the size of the current building, in growing world-wide demand.
Edwards Lifesciences (NYSE:EW) doubled a heart valve manufacturing facility in Singapore, saying it needs the boost to keep up with growing demand for tissue heart valves.
Dr. Mehmet Oz, best known for his day-time health-related talk-show, is slated to make an appearance in a legal feud between Medtronic and Edwards Lifesciences.
FDA regulators slap their highest-risk Class I label on a recall of Edwards Lifesciences' EMBOL-X Glide Protection Systems after the company reports that some of the cannula tips are deformed.